

## Dr. Freddy Yip, PhD

Counsel



fyp@cooley.com

Life Sciences Corporate Partnering and Licensing  
Life Sciences and Healthcare  
Asia

+852 3758 1235

Hong Kong

Freddy focuses his practice on licensing, collaboration, joint venture and complex intellectual property transactions in the life sciences industry, particularly in cross-border settings. He also has significant experience in representing life sciences companies and research institutes in clinical trial, manufacturing, supply, and services agreements.

Freddy earned his PhD in molecular cell biology from the University of New South Wales in Australia. Prior to joining the legal profession, Freddy worked in various research and development positions in the biopharmaceutical industry for several years, including in a multinational pharmaceutical company in Australia and a biotech company in Hong Kong, focusing on CMC and preclinical development of novel protein-based drugs, such as an anti-cancer monoclonal antibody and a hemoglobin-based oxygen carrier.

### Freddy's experience includes representation of:

- **Jiangsu Hengrui Pharmaceuticals** in its up to US\$15.2 billion global strategic collaboration and license agreements with Bristol Myers Squibb (BMS) to advance a portfolio of 13 early-stage programs in oncology, hematology and immunology. (2026)
- **InnoCare Pharma Limited**, a commercial stage biopharmaceutical company, in its global license agreement with Zenas BioPharma for the development, manufacturing, and commercialization of three autoimmune product candidates, including orelabrutinib, a highly selective CNS-penetrant, oral small molecule BTK inhibitor now in Phase 3 development for progressive forms of multiple sclerosis. (2025)
- **Mabwell Bioscience**, an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain, in its exclusive license agreement with Aditum Bio to launch Kalexo Bio for the worldwide development, manufacturing, and commercialization of 2MW7141, a novel dual-target small interfering RNA (siRNA) candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease events. (2025)
- **Jiangsu Hengrui Pharmaceuticals** in its exclusive license agreement with Braveheart Bio for the worldwide (excluding mainland China, Hong Kong, Macao, and Taiwan) development, manufacturing, and commercialization of HRS-1893, a small-molecule inhibitor of cardiac myosin with best-in-class potential. (2025)
- **Argo Biopharma**, a clinical-stage biotechnology company focused on developing next-generation small interfering RNA (siRNA) therapeutics, in its additional strategic collaboration with Novartis for multiple cardiovascular assets in Argo's pipeline, including an option granted to Novartis to license ex-

China rights to two discovery-stage next-generation molecules for the treatment of severe hypertriglyceridemia and mixed dyslipidemia and a right of first negotiation to BW-00112 (ANGPTL3), as well as an ex-China license granted to Novartis with reciprocal options to share in profit and loss in the US and China for an additional hepatic-delivered siRNA candidate currently in IND-enabling studies. (2025)

- **Jiangsu Hengrui Pharmaceuticals** in its up to \$12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline. (2025)
- **Jiangsu Hengrui Pharmaceuticals** in its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology. (2025)
- **Suzhou Puhe BioPharma**, a biotechnology company dedicated to the research and development of innovative small-molecule precision therapeutics, on its global license agreement with Bayer for Puhe BioPharma's oral, small-molecule protein arginine methyltransferase 5 inhibitor that selectively targets metabolic enzyme 5'-deoxy-5'-methylthioadenosine phosphorylase-deleted tumors. (2025)
- **Sangamo Therapeutics**, a clinical-stage biotechnology company, in its worldwide exclusive license agreement with Eli Lilly to deliver their intravenously administered genomic medicines to treat certain diseases of the central nervous system. (2025)
- **Tiannuo Jiancheng Pharma**, a 50/50 joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in its exclusive license agreement with Prolium Bioscience (NewCo) for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody. (2025)
- **ARS Pharmaceuticals**, a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, in its exclusive agreement with global allergy leader alk to commercialize neffy® in Europe, Canada and Other Geographies Outside the United States. (2024)
- **ProfoundBio**, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, in its definitive agreement to be acquired for \$1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases. (2024)
- **IASO Biotherapeutics**, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, on its new set of collaborations with Umoja Biopharma for the development and commercialization of novel ex vivo and in vivo cell and gene therapies. (2024)
- **JW Therapeutics**, an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, in its exclusive collaboration with 2seventy bio, for the co-development and commercialization of a chimeric antigen receptor (CAR) T-cell therapy product for autoimmune diseases (AID program) in Greater China. (2024)
- **SystImmune**, a clinical-stage biopharmaceutical company, in its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune's BL-B01D1. (2023)
- **Jiangsu Hengrui Pharmaceuticals** in its global licensing agreement with Elevar Therapeutics to commercialize and develop anti-PD-1 antibody camrelizumab in combination with rivoceranib worldwide, excluding Greater China and Korea. (2023)
- **Jiangsu Hengrui Pharmaceuticals**, a global pharmaceutical company focused on scientific and technological innovation, in its exclusive license agreement with Merck for its next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) inhibitor, HRS-1167. (2023)
- **Eccogene**, a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally, in its exclusive license agreement with AstraZeneca to develop and commercialize Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities. (2023)

- **Senti Biosciences**, a biotechnology company, in its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners to establish GeneFab. (2023)
- **Cholesgen**, a biopharmaceutical company focusing on metabolic diseases, in its three-year research collaboration and licensing agreement with AstraZeneca. (2023)
- **Zai Lab**, a research-based commercial-stage biopharmaceutical company, in its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as part of Zai Lab's efforts to build its portfolio of potential first- and/or best-in-class antibody-drug conjugate (ADC) products. (2023)
- **Apollo Endosurgery**, a medical device company, in its agreement to be acquired by Boston Scientific in an all-cash transaction with an enterprise value of approximately \$615 million. (2022)
- **Tmunity**, a clinical-stage biotechnology company, in its agreement to sell to Kite, a global biopharmaceutical company. (2022)
- Global investment firm **Sixth Street** in its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. (2022)
- **Jadeite Medicines**, a clinical-stage biopharmaceutical company headquartered in Tokyo, Japan, in its definitive agreement with Albireo Pharma Inc, a wholly-owned subsidiary of Ipsen, for the development and commercialization in Japan of odevixibat, a potent, non-systemic iBAT inhibitor being developed and commercialized by Ipsen in the U.S. and Europe. (2022)
- **TransThera Biosciences** in its licensing transaction with LG Chem Life Sciences to grant exclusive license related to TT-01025, an SSAO/VAP-1 inhibitor, for development and commercialization in all territories, excluding China\*
- **Sichuan Kelun-Biotech Biopharmaceutical Co.** in its exclusive license and collaboration agreement with Merck for development rights (excluding China) of an oncology drug candidate\*
- **Cugene** in its exclusive worldwide license option agreement with AbbVie for the development and commercialization of its novel IL-2 mutein drug candidates\*
- **Shenzhen Xbiome Biotech Co.** in its licensing transaction with Aurealis Therapeutics AG to obtain an exclusive license for the development and commercialization of AUP-16, a four-in-one cell and gene therapy drug for chronic wounds and other inflammatory degenerative diseases, in Greater China\*
- **Huadong Medicine Co.** in its licensing transaction with AKSO Biopharmaceutical to obtain an exclusive license for the development and commercialization of AB002, a dual-target biospecific fusion protein inhibiting immune checkpoint and activating NK cells for the treatment of solid tumors, in the Asia-Pacific region (excluding Japan)\*
- **SciNeuro Pharmaceuticals** in its collaboration and license agreement with Mabyon AG for the discovery, development and commercialization of human antibodies for treatment of neurological diseases\*
- **Arrivent Biopharma** in its collaboration and license agreement with Aarvik Therapeutics for the discovery, development and commercialization of an oncology-focused drug candidate\*
- **Beijing Tide Pharmaceutical Co.** in its licensing transaction with Graviton Bioscience Corp. to grant exclusive license related to TDI91, a ROCK2 inhibitor, for development and commercialization in all territories, excluding China\*
- **Hinova Pharmaceuticals** in its licensing transaction with amcure to obtain an exclusive license for the development and commercialization of AMC303 in oncology in Greater China\*
- **Zai Lab** in its broad strategic collaboration and license agreement with MacroGenics to develop and commercialize preclinical bispecific antibodies in oncology, involving up to four immuno-oncology molecules\*
- **MyoKardia** in its strategic collaboration with LianBio to develop and commercialize mavacamten in China and other Asian territories\*
- **Regenacy Pharmaceuticals** in its formation of Beijing 3E-Regenacy Pharmaceuticals Co., a joint venture with 3E Bioventures Capital, for the development of Regenacy's lead compound ricolinostat, a HDAC6 inhibitor, in mainland China, Hong Kong and Macau\*
- **I-Mab** in its strategic partnership with Kalbe Genexine Biologics, a joint venture of Kalbe Farma Tbk

and Genexine, relating to commercialization rights of TJD5 (an anti-CD73 antibody)\*

- **EpicentRx** in its licensing transaction with SciClone to grant an exclusive license related to RRx-001, a small molecule immunotherapy targeting CD47-SIRP $\alpha$ , a treatment of small-cell lung cancer in Greater China\*
- **Alphamab** in its strategic partnership with Sanofi relating to clinical development of an anti-HER2 bispecific antibody\*
- **Laekna Therapeutics** in obtaining from Novartis an exclusive global license on FAZ053 (an anti-PD-L1 antibody)\*
- **Shenzhen Salubris** in its licensing and collaboration transaction with Japan Tobacco to obtain an exclusive license related to a hypoxia inducible factor inhibitor in Greater China\*

\* Transaction handled prior to joining Cooley

## Education

The University of Hong Kong Postgraduate Certificate in Laws, 2017

Metropolitan Manchester University LLB, honors, 2015

The University of New South Wales PhD, Molecular Cell Biology, 2009

The University of New South Wales BSc, Molecular Biology and Chemistry, honors, 2006

## Admissions & Credentials

Hong Kong